➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Baxter
Dow
Moodys
Mallinckrodt

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

BETASERON Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: BETASERON
Recent Clinical Trials for BETASERON

Identify potential brand extensions & biosimilar entrants

SponsorPhase
BiogenPhase 4
National Institutes of Health (NIH)Phase 2
National Multiple Sclerosis SocietyPhase 2

See all BETASERON clinical trials

Company Disclosures: US Patents for BETASERON

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Cetus Corporation (Emeryville, CA) 2039-03-29 RX Orphan company
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Cetus Corporation (Emeryville, CA) 2004-03-28 RX Orphan company
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Cetus Corporation (Emeryville, CA) 2003-05-13 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for BETASERON

These patents were identified by searching patent claims

Supplementary Protection Certificates for BETASERON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C 2016 046 Romania   Start Trial PRODUCT NAME: DACLIZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1107; DATE OF NATIONAL AUTHORISATION: 20160701; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1107; DATE OF FIRST AUTHORISATION IN EEA: 20160701
SPC/GB96/019 United Kingdom   Start Trial
SZ 10/1996 Austria   Start Trial PRODUCT NAME: BETAFERON - INTERFERON BETA-1B
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Merck
Dow
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.